Kevin Lundquist was named Chief Financial Officer of Outlook Therapeutics, Inc. As of November 6, 2026, Outlook Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on August 27, 2026, naming 1 appointment (Form 8-K, August 27, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Outlook Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Outlook Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-08-27. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Outlook Therapeutics, Inc. files it.
Also on the record for Outlook Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 13, 2026 | Stake report, Schedule 13G, by Empery Asset Management, LP | 8.73% of the class | 5%+ stakes | Source |
| August 19, 2026 | Stake report, Schedule 13G, by CVI Investments, Inc. | 9.9% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13D/A, by GMS Ventures & Investments | 16.4% of the class | 5%+ stakes | Source |
| June 1, 2026 | Stake report, Schedule 13D/A, by GMS Ventures & Investments | 22.9% of the class | 5%+ stakes | Source |
| April 24, 2026 | Stake report, Schedule 13G, by Mitchell P. Kopin | 4.99% of the class | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G/A, by Sphera Funds Management Ltd. | 4.69% of the class | 5%+ stakes | Source |
| October 21, 2025 | Stake report, Schedule 13G/A, by Empery Asset Management, LP | 4.99% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Great Point Partners, LLC | 4.99% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by TANG CAPITAL MANAGEMENT, LLC | 3.4% of the class | 5%+ stakes | Source |
| July 31, 2025 | Stake report, Schedule 13G, by Empery Asset Management, LP | 7.57% of the class | 5%+ stakes | Source |
| January 27, 2025 | Form D, private offering | — | Form D page | Source |
| October 10, 2024 | Court case: Lewis v. Outlook Therapeutics, Inc., District Court, D. Delaware | — | Court records | Source |
Selling to them or working with them? See who runs Outlook Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Outlook Therapeutics, Inc. and the records around it.
Outlook Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Company profile and every filing May 2026
- Who owns it
Companies that share a holder
- Sphera Funds Management Ltd. also filed stake reports on 2 other companies: Tenax Therapeutics, Inc. (Oct 2026), ProMIS Neurosciences Inc. (Feb 2026)
- Great Point Partners, LLC also filed stake reports on 14 other companies: LeonaBio, Inc. (Nov 2026), Research Alliance Corporation III (Sep 2026), JATT III Acquisition Corp (Sep 2026)
- Empery Asset Management, LP also filed stake reports on 21 other companies: Dyadic International Inc. (Oct 2026), Femasys Inc. (Oct 2026), Clene Inc. (Oct 2026)
Watch Outlook Therapeutics, Inc.
Get an email when Outlook Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Outlook Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Outlook Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Outlook Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 14 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-27 | In | Chief Financial Officer | 8-K, 2026-08-27 |
Who leads Outlook Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Kevin Lundquist, appointed (filed 2026-08-27).
New leaders reset buying decisions — get the Full Report on Outlook Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportWatch Outlook Therapeutics, Inc. (free up to 3)
Find people with the same kind of experience as the Chief Financial Officer at Outlook Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Outlook Therapeutics, Inc.Every change, in the filing's words
Appointed: Kevin Lundquist, Chief Financial Officer
In connection with Mr. Kenyon's departure, on August 27, 2026, the Board appointed Kevin Lundquist as the Company's Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer, effective as of the Transition Date.
- Chief Financial Officer Transition On August 23, 2026, Outlook Therapeutics, Inc. (the "Company") and Lawrence A. Kenyon, the Company's Chief Financial Officer, Treasurer and Corporate Secretary and a member of the Company's Board of Directors (the "Board"), mutually agreed that Mr. Kenyon would cease serving in the roles of Chief Financial Officer, Treasurer, Corporate Secretary, principal financial officer and principal accounting officer, effective September 1, 2026 (the "Transition Date").
- Mr. Lundquist, age 58, most recently served as Chief Financial Officer of CapsoVision Inc. (Nasdaq: CV), a commercial stage medical technology company, from October 2024 to February 2026, where he managed all aspects of finance and operations and led the company through its initial public offering.
- Prior to that, Mr. Lundquist served as Chief Financial Officer of Abzena Biologics, Inc., a biotechnology company, from January 2022 to December 2023.
- From August 2020 to January 2022, Mr. Lundquist served as Vice President of Finance of Revance, Inc. (Nasdaq: RVNC), a biotechnology company.
- Mr. Lundquist also previously served in various other finance roles, including Senior Director of Global Manufacturing Finance of Roche, Chief Financial Officer of Caterpillar Japan, Director of Finance Operations of Caterpillar India and Director of International Business Development for Abbott Laboratories.
Outlook Therapeutics, Inc.'s funding history
Tools for this story
Each opens in a new tab, filled in for Outlook Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.